<DOC>
	<DOCNO>NCT02538848</DOCNO>
	<brief_summary>To investigate safety tolerability HTD4010 single ascending dos ( SAD ) healthy volunteer</brief_summary>
	<brief_title>Study HTD4010 Healthy Volunteers</brief_title>
	<detailed_description>Safety , tolerability pharmacokinetics ( PK ) assessments outcome measure .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>For volunteer SAD : 1 . Body mass index ( BMI ) ≥18.0 ≤ 30.0 kg/m2 2 . Nondiabetic , fast plasma glucose &lt; 5.6 mmol/L 3 . Females must nonpregnant nonlactating , either surgically sterile ( e.g. , tubal occlusion , hysterectomy , bilateral salpingectomy , bilateral oophorectomy ) postmenopausal ≥12 month . Males must surgically sterile , abstinent engage sexual relation childbearing potential , participant partner must use acceptable , highly effective , contraceptive method screen period 60 day last dose Study Drug . 4 . Ability provide write informed consent . 1 . Systolic blood pressure &gt; 160 mmHg and/or diastolic blood pressure &gt; 90 mmHg screening . 2 . Pregnant lactate woman 3 . Participation investigational study within 30 day prior dose 5 halflives within last dose investigational product whichever longer . 4 . Current use prescription overthecounter ( OTC ) medication , include herbal product supplement , within 14 day prior Day 1 5 halflives , whichever longer . Use ≤2g paracetamol per day allow prior study Investigator discretion . 5 . Any use nonsteroid antiinflammatory drug ( NSAIDs ) within 7 day prior dose . 6 . History major surgery within 6 month prior Screening 7 . History serious adverse reaction hypersensitivity product component . 8 . Use parenterally administered protein antibody within 12 week screen . etc .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>